MRCP
RadiationSubjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription
NCT Number: NCT04095195
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Istituto Clinico Humanitas, Rozzano, Milan, Italy
Pancreatic cancer is a devastating disease with a dismal prognosis. One of the ways to improve survival might be early detection.
Within years, many predisposing diseases or genetic conditions have been identified, thus screening/surveillance have been established worldwide.
A registry of subjects at risk of pancreatic cancer will has been built up to investigate the possibility of diagnosis pancreatic cancer, or one if its predisposing lesions.
Inclusion criteria
will be adopted as "enrollment criteria". According to this, individuals > 18 years old will be enrolled; their familiar history and/or genetic predisposition will be collected, as well as current or previous medical records/medications data. Thereafter, according to specific age-based criteria, those individuals initially enrolled will be will be considered for a "surveillance protocol" ("interventional follow-up criteria") and they will be submitted to Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography according to the pancreatologist's prescription at each participating center.
Individuals suffering from the following conditions will be enrolled:
familial pancreatic cancer; Peutz-Jeghers syndrome; a known BRCA-2, BRCA-1, PALB2, or p16 mutation with at least one first- or second-degree relative suffering from pancreatic cancer; hereditary pancreatitis; FAMMM syndrome; Lynch syndrome with at least one first- or second-degree relative suffering from pancreatic cancer.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
to enter the registry:
Inclusion criteria
to join the "radiologic follow-up":
Exclusion criteria
Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription
Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription
Time frame: 25 years
Number of malignant and pre-malignant lesions diagnosed over time
Time frame: 25 years
Identification of risk factors for malignant or pre-malignant lesions diagnosis
Contact information is provided by the study sponsor or research team.
Salvatore Paiella, MD, PhD
CONTACT
Silvia Carrara, MD
CONTACT
Associazione Italiana per lo Studio del Pancreas
Other
Italian Registry of Families At Risk of Pancreatic Cancer
Acronym: IRFARPC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07700992
Cysts, Digestive System Diseases
Milan, MI, Italy
View Trial DetailsNCT04743479
Chronic Disease, Chronic Pancreatitis
Shanghai, China
View Trial DetailsNCT03693378
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases
Stanford, California, United States
View Trial DetailsNCT00835133
Familial Pancreatic Cancer, Melanoma
Rochester, Minnesota, United States
View Trial Details